You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel Antibacterial Agents That Target DNA Replication in Mycobacterium tuberculo
SBC: Achillion Pharmaceuticals, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Mycobacterium tuberculosis (MTB) is probably the most ubiquitous microbial pathogen in the world today infecting one-third of the total population and causing millions of active tuberculosis (TB) cases each year. The economic costs are substantial and more than one million people die of TB infections each year. Before the arrival of antimicrobial therapy, TB wa ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Development of a method to multiplex ChIP-SEQ and ChIP-chip experiments
SBC: AFFOMIX, INC. Topic: NHGRIDESCRIPTION (provided by applicant): The immediate objective of our research is to generate a method that will enable researchers to multiplex Chromatin ImmunoPreciptation-Sequencing (ChIP-Seq) analysis in a single Next generation DNA sequencing run. In the to-be-developed method: i) a set of antibodies directed against specific DNA-binding proteins are uniquely bar-coded with a DNA 'ZipCode;' ii) ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
High-throughput screening and identification of scFv antibodies against glycosyla
SBC: AFFOMIX, INC. Topic: NCRRDESCRIPTION (provided by applicant): The specific goal of this proposal is to develop a high-throughput method to identify scFv antibodies that recognize post-translationally modified proteins. We propose to complete a proof-of-concept for a new type of affinity screening process based on emulsion, secretion, and capture, which we term ESCape . In the proposed phage ESCape method, E. coli transfo ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
A bifunctional antibody screening system for both phage display and yeast two-hyb
SBC: AFFOMIX, INC. Topic: NIAIDDESCRIPTION (provided by applicant): This is a proposal to establish a proof-of-principle for a vector system to isolate high-affinty antibodies through selective rounds in both yeast and Escherichia coli. Antibodies have quickly become extremely useful as therapeutic medicines to treat a wide-variety of disorders. We propose to develop a means of making the discovery of immunotherapeutics faster ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Synthetic nanocapsule malaria vaccines
SBC: ARTIFICIAL CELL TECHNOLOGIES INC Topic: NIAIDDESCRIPTION (provided by applicant): The goal of this project is to produce novel synthetic malaria vaccines based on epitopes of the circumsporozoite (CS) protein of Plasmodium falciparum, the causative agent of human malaria. Malaria is one of the major diseases in the developing world, causing 200-500 million new infections and over 1 million deaths each year, primarily in young children in Af ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Protein Microarray System for Rheumatoid Arthritis
SBC: CIENCIA INC Topic: NIAIDDESCRIPTION (provided by applicant): The long-term objective of the proposed effort is to develop an autonomous clinical diagnostics system for monitoring normal and diseased immune function that occurs in the context of rheumatoid arthritis, infection, inflammation, asthma, autoimmune disease, and neoplasia. This system will be a microarray-based bioassay platform that specifically captures d ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Beta-Globin Gene Correction Using Peptide Nucleic Acids for the Treatment of Sick
SBC: HELIX THERAPEUTICS, LLC Topic: NHLBIDESCRIPTION (provided by applicant): This is a proposal to test the feasibility of using triplex-forming oligonucleotides to correct the sickle cell disease (SCD) mutation in human CD34+ cells. SCD is one of the most common human genetic diseases and is the result of one specific inherited mutation in the 2-globin gene. Hydroxyurea is currently the only FDA-approved treatment for SCD. Both support ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Identification of Oligodendrocyte Stimulators
SBC: JS GENETICS, LLC Topic: NINDSDESCRIPTION (provided by applicant): Oligodendrocytes (OLs) are the myelinating cells of the central nervous system and play a critical role in white matter formation. Serious clinical disorders affect central nervous system white matter during early development. These conditions include periventricular white matter injury (PWMI), which affects up to 20% of very low birth weight premature infants. ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel Diagnostics for Fragile X Syndrome
SBC: JS GENETICS, LLC Topic: NICHDDESCRIPTION (provided by applicant): Fragile X Syndrome (FRAX) is the most common genetic cause of mental retardation in males. FRAX is caused by the expansion of a CGG trinucleotide repeat of the 5' untranslated region (UTR) of the FMR1 gene. In normal individuals, the 5' UTR of the FMR1 gene contains 5 to 45 CGG repeats; however, individuals with FRAX have over 200 repeats. Presently, Southe ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
A serologic assay to measure successful Lyme borreliosis antibiotic therapy
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION (provided by applicant): Lyme disease, due to infection with the Ixodes tick-transmitted spirochete Borrelia burgdorferi, is the most common vector-borne disease in the United States, with over 20,000 cases reported to the CDC annually. There is controversy over the length of antibiotic therapy that is necessary to achieve a clinical cure for Lyme disease. Serologic tests (ELISA and im ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health